New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
10:02 EDTSGGH, MTLS, XNET, STAG, TCPI, REGN, FAF, ECR, LCUT, GPRO, AMPH, IMPR, FNF, ADPTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adeptus Health (ADPT) initiated with a Buy at Dougherty... Amphastar (AMPH) initiated with a Buy at Jefferies... Eclipse Resources (ECR) initiated with a Neutral at SunTrust... Fidelity National (FNF) initiated with a Buy at SunTrust... First American (FAF) initiated with a Buy at SunTrust... GoPro (GPRO) initiated with a Hold at Stifel... Imprivata (IMPR) initiated with an Outperform at Wells Fargo... Lifetime Brands (LCUT) initiated with a Buy at Sidoti... Materialise (MTLS) initiated with a Buy at BB&T... Regeneron (REGN) initiated with a Buy at Argus... STAG Industrial (STAG) initiated with a Buy at Sandler O'Neill... Signature Group (SGGH) initiated with a Buy at B. Riley... TCP International (TCPI) initiated with a Buy at Canaccord... Tessera (TSRA) initiated with a Buy at Craig-Hallum... Xunlei (XNET) initiated with a Perform at Oppenheimer.
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
16:09 EDTGPRONicholas Woodman reports 44.9% passive stake in GoPro
07:46 EDTGPROGoPro February volatility elevated into Q4 and outlook
Subscribe for More Information
06:34 EDTREGNObama to propose $215M for major medical program, CNBC says
Subscribe for More Information
January 29, 2015
09:07 EDTREGNHead researchers of Vertex, Regeneron, Merck invited to White House, CNBC says
Subscribe for More Information
06:03 EDTGPROGoPro Q4 results have upside potential, says JPMorgan
JPMorgan sees potential upside to consensus estimates when GoPro reports Q4 results on Thursday, February 5. The firm says its channel checks intra-quarter indicated strength across the U.S., with product mix skewed toward the Black and Silver editions. JPMorgan reiterates an Overweight rating on GoPro with a $70 price target.
January 28, 2015
10:54 EDTMTLSStratasys shares at 'compelling entry point' after pullback, says Canaccord
Subscribe for More Information
January 27, 2015
10:18 EDTGPROGoPro mentioned cautiously by Devonshire Capital
Subscribe for More Information
January 26, 2015
05:14 EDTREGNRegeneron, Sanofi announce BLA for Praluent accepted for priority review by FDA
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the Biologics License Application, or BLA, for Praluent, alirocumab. Under the Prescription Drug User Fee Act, or PDUFA, the goal for a priority review is six months, for a target action date of July 24. Alirocumab is an investigational monoclonal antibody targeting PCSK9 that is intended for the treatment of patients with hypercholesterolemia. The BLA for Praluent contains data from more than 5,000 patients, including 10 Phase 3 ODYSSEY trials. Together with additional ongoing studies including ODYSSEY OUTCOMES, the ODYSSEY clinical trial program will include more than 23,500 patients at more than 2,000 study centers in double-blind, randomized, placebo-and active-controlled trials ranging from 24 weeks to approximately 5 years. Earlier this month, the companies announced that the European Medicines Agency accepted for review the Marketing Authorization Application for Praluent in the European Union. The EMA and FDA have conditionally accepted Praluent as the trade name for alirocumab. The safety and efficacy of alirocumab have not been fully evaluated by any regulatory authority.
January 25, 2015
17:37 EDTFNFRemy International looks attractive, Barron's says
Subscribe for More Information
January 23, 2015
16:32 EDTGPROOn The Fly: Closing Wrap
Subscribe for More Information
12:56 EDTGPROGoPro rallies, but faces a possible challenge
Subscribe for More Information
10:03 EDTGPROGoPro partners with NHL, NHLPA
Subscribe for More Information
08:55 EDTSTAGSTAG Industrial price target raised to $30 from $27 at RW Baird
Subscribe for More Information
07:39 EDTREGNRegeneron announces EYLEA Injection recommended for approval in EU
Subscribe for More Information
January 22, 2015
09:38 EDTGPROGoPro estimates raised at Cleveland Research
Subscribe for More Information
08:32 EDTFAFFirst American raises quarterly dividend 4% to 25c per share
Subscribe for More Information
January 21, 2015
10:16 EDTREGNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
07:09 EDTMTLSPiper positive on Stratasys, cautious on 3D Systems after survey
Subscribe for More Information
January 20, 2015
11:00 EDTGPROGoPro slides further, levels to watch
The stock has been in a persistent downtrend since the start of the year. Today the shares are getting closer to a test of support from late summer of last year. At the current price of $46.50, next support is at $44.85 and then at $43.10. Resistance is at $48.23.
January 18, 2015
17:12 EDTGPROGoPro shares could drop further, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use